Martin P. Sutter - 07 Jun 2024 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Director
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
07 Jun 2024
Transactions value $
$0
Form type
4
Date filed
11 Jun 2024, 20:47
Previous filing
13 Jun 2023
Next filing
13 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise $0 +30.4K +107.24% $0.00 58.7K 07 Jun 2024 Direct
holding BVS Class A Common Stock 13M 07 Jun 2024 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -30.4K -100% $0.00* 0 07 Jun 2024 Class A Common Stock 30.4K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 12,096,702 shares of Class A Common Stock held by EW Healthcare Partners Acquisition Fund, L.P. ("Essex Stockholder") and 924,622 shares of Class A Common Stock held by White Pine Medical, LLC ("White Pine"). EW Healthcare Partners Acquisition Fund UGP, LLC ("General Partner") is the general partner of EW Healthcare Partners Acquisition Fund GP, L.P., which is the general partner of Essex Stockholder, which is the managing member of White Pine. Messrs. Sutter, Vainio, Eastman, and Barry (collectively, the "Managers") are the managers of the General Partner. The Managers disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F3 The RSUs vested on June 7, 2024.